US2015250863A1PendingUtilityA1

Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase

61
Assignee: UNIV COLORADOPriority: Apr 18, 1997Filed: Feb 25, 2014Published: Sep 10, 2015
Est. expiryApr 18, 2017(expired)· nominal 20-yr term from priority
A01K 2217/05C12Q 1/6895C12N 2310/315C12Q 2600/158C12N 2310/15C12Q 2600/156C12N 15/113C12N 9/1241A61K 38/00A61K 48/00C12N 15/1137C07K 16/40A61K 2039/55505C12N 9/1276A61P 35/00C07K 2319/00A61K 2039/55566C12Y 207/07049C07K 14/43504A61K 2039/575A61K 2039/55511A61K 39/39A61K 39/0005A61K 2039/55516A61K 2039/55544A61K 39/0011A61K 39/001157
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide comprising 10 or more consecutive amino acids of SEQ. ID NO:2, which can elicit an adaptive immune response against human telomerase reverse transcriptase (hTRT; SEQ. ID NO:2). 
     
     
         2 . The isolated polypeptide of  claim 1 , comprising 20 or more consecutive amino acids of SEQ. ID NO:2. 
     
     
         3 . The isolated polypeptide of  claim 1 , comprising 50 or more consecutive amino acids of SEQ. ID NO:2. 
     
     
         4 . The isolated polypeptide of  claim 1 , comprising 100 or more consecutive amino acids of SEQ. ID NO:2. 
     
     
         5 . The polypeptide of  claim 1 , containing an amino acid sequence selected from SEQ. ID NO:112, SEQ. ID NO:113, SEQ. ID NO:114, SEQ. ID NO:115, SEQ. ID NO:116, and SEQ. ID NO:117. 
     
     
         6 . The polypeptide of  claim 1 , which is at least 98% identical to full-length hTRT (SEQ. ID NO:2). 
     
     
         7 . The polypeptide of  claim 6 , which does not retain the telomerase catalytic activity of native human telomerase reverse transcriptase. 
     
     
         8 . A pharmaceutical composition comprising the polypeptide of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         9 . An immunogenic composition that elicits an adaptive immune response against hTRT (SEQ. ID NO:2), comprising a peptide and an adjuvant, wherein the peptide comprises 10 or more consecutive amino acids of SEQ. ID NO:2. 
     
     
         10 . The composition of  claim 9 , comprising 50 or more consecutive amino acids of SEQ. ID NO:2. 
     
     
         11 . The composition of  claim 9 , wherein the adjuvant is selected from Freund's adjuvant, a mineral gel, aluminum hydroxide, lysolecithin, pluronic polyol, a polyanlon, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP),  Bacillus  Calmette-Guerin, and  Corynebacterium parvum.    
     
     
         12 . A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the composition of  claim 9 . 
     
     
         13 . The method of  claim 12 , further comprising assessing whether a telomerase-specific immune response is elicited as a result of the administration. 
     
     
         14 . An immunogenic composition that induces anti-hTRT specific antibody, comprising a peptide and an adjuvant, wherein the peptide consists of 5 to 10 consecutive amino acids of SEQ. ID NO:2. 
     
     
         15 . A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the composition of  claim 14 . 
     
     
         16 .- 20 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.